Advances in sarcoma genomics and new therapeutic targets

Nat Rev Cancer. 2011 Jul 14;11(8):541-57. doi: 10.1038/nrc3087.


Increasingly, human mesenchymal malignancies are being classified by the abnormalities that drive their pathogenesis. Although many of these aberrations are highly prevalent within particular sarcoma subtypes, few are currently targeted therapeutically. Indeed, most subtypes of sarcoma are still treated with traditional therapeutic modalities, and in many cases sarcomas are resistant to adjuvant therapies. In this Review, we discuss the core molecular determinants of sarcomagenesis and emphasize the emerging genomic and functional genetic approaches that, coupled with novel therapeutic strategies, have the potential to transform the care of patients with sarcoma.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Genome
  • Genomics*
  • Humans
  • Mice
  • Mutation
  • Sarcoma / drug therapy
  • Sarcoma / genetics*
  • Signal Transduction


  • Antineoplastic Agents